High Mobility Group Box 1: The Protein at the Crossroads of

High Mobility Group Box 1 (HMGB1) is a nuclear protein that has garnered significant attention in recent years due to its role in inflammation, cell death, and disease. First identified in 1999 by Haggren et al., HMGB1 has been shown to be a key mediator of inflammation, with elevated levels observed in conditions such as sepsis, arthritis, and cancer. The protein's ability to bind to various receptors, including the receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs), allows it to modulate the immune response and promote the release of pro-inflammatory cytokines. With a Vibe score of 8, HMGB1 has become a major focus of research, with studies suggesting its potential as a therapeutic target for the treatment of inflammatory and autoimmune disorders. However, the protein's role in human disease is complex, and further research is needed to fully understand its mechanisms of action. As research continues to uncover the intricacies of HMGB1, it is likely that our understanding of its functions will continue to evolve, with potential implications for the development of novel therapeutic strategies.